NDATOPICALGELPriority Review
Approved
Dec 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FILSUVEZ (birch triterpenes) is a topical gel approved in December 2023 for wound healing applications. The product contains naturally derived triterpenes that promote tissue repair and regeneration when applied directly to affected areas. The mechanism of action leverages the anti-inflammatory and wound-healing properties of birch-derived compounds.
Growth12.2 years to LOE
Early-stage growth product with minimal competitive pressure; brand team will focus on market penetration and provider education in the wound care channel.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez
Started Dec 2024
170 enrolled
Epidermolysis Bullosa, DystrophicEpidermolysis Bullosa, Junctional
Career Relevance
Working on FILSUVEZ offers career professionals an opportunity to build a new market category with zero direct competition and strong patent protection through 2039. This early-stage growth product provides visibility and autonomy for those comfortable with launch-phase execution and channel development in specialty wound care.
Brand Manager
Worked on FILSUVEZ at Chiesi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.